View Older Stories

Feb 25, 2026 07:19AM FDA accepts Vanda's drug application for rare skin disorder treatment

Jan 12, 2026 09:55AM AnaptysBio (ANAB) Reiterated at Buy by UBS: Trial Now Set for July 2026

Jan 12, 2026 04:05AM Leerink Partners Reiterates Outperform Rating on AnaptysBio (ANAB)

Jan 8, 2026 06:03PM AnaptysBio files motion to dismiss Tesaro breach claim in royalty dispute

Jan 7, 2026 12:39AM UBS Assumes AnaptysBio (ANAB) at Buy

Dec 19, 2025 09:06AM TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'

Dec 15, 2025 07:01AM Vanda submits FDA application for rare skin disorder drug

Dec 11, 2025 07:38AM AnaptysBio (ANAB) PT Lowered to $56 at Stifel

Nov 26, 2025 04:05PM AnaptysBio files lawsuit against Tesaro and GSK over license deal

Nov 21, 2025 03:56AM AnaptysBio files lawsuit against Tesaro over collaboration breach

Nov 10, 2025 09:00AM Anaptys discontinues ulcerative colitis trial after rosnilimab fails endpoints

Nov 10, 2025 08:57AM Anaptysbio (ANAB) Halted, News Pending

Oct 29, 2025 09:15AM Anaptys reports positive phase 2b trial data for rosnilimab in arthritis

Oct 15, 2025 07:24AM H.C. Wainwright Reiterates Buy Rating on AnaptysBio (ANAB)

Oct 14, 2025 06:29AM AnaptysBio (ANAB) PT Raised to $72 at Piper Sandler

Oct 13, 2025 09:16AM AnaptysBio to present rosnilimab rheumatoid arthritis data at ACR meeting

Oct 13, 2025 05:29AM Barclays Starts AnaptysBio (ANAB) at Overweight

Oct 1, 2025 01:20PM Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'

Oct 1, 2025 01:13PM FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'

Sep 30, 2025 10:19AM AnaptysBio (ANAB) PT Raised to $37 at Leerink Partners

Sep 30, 2025 06:48AM AnaptysBio (ANAB) PT Raised to $59 at H.C. Wainwright

Sep 30, 2025 06:44AM Guggenheim Reiterates Buy Rating on AnaptysBio (ANAB)

Sep 29, 2025 04:07PM Anaptys plans split into royalty and biopharma companies by 2026

Sep 29, 2025 04:01PM Anaptysbio (ANAB) halted, news pending

Sep 17, 2025 07:41AM Truist Securities Reiterates Hold Rating on AnaptysBio (ANAB)

Aug 7, 2025 06:20AM AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 18c

Jun 4, 2025 07:15AM Stifel Reiterates Buy Rating on AnaptysBio (ANAB)

Jun 4, 2025 06:27AM TD Cowen Reiterates Buy Rating on AnaptysBio (ANAB)

Jun 4, 2025 06:06AM H.C. Wainwright Upgrades AnaptysBio (ANAB) to Buy

Jun 3, 2025 04:07PM Anaptysbio (ANAB) Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

May 28, 2025 07:10AM AnaptysBio (ANAB) PT Raised to $90 at Guggenheim

May 27, 2025 04:39PM Anaptysbio (ANAB) announces updated data from Phase 2b trial on Rosnilimab

May 21, 2025 06:16AM Wolfe Research: 'Bullish long-term on ANAB'

May 5, 2025 08:50PM AnaptysBio, Inc. (ANAB) Tops Q1 EPS by 2c

Mar 24, 2025 09:15AM Anaptysbio (ANAB) Announces Stock Repurchase Plan

Mar 4, 2025 06:43AM H.C. Wainwright Reiterates Neutral Rating on AnaptysBio (ANAB)

Feb 28, 2025 12:26PM AnaptysBio (ANAB) PT Raised to $52 at Guggenheim

Feb 27, 2025 05:11PM AnaptysBio, Inc. (ANAB) Tops Q4 EPS by 90c

Feb 13, 2025 06:49AM AnaptysBio (ANAB) PT Raised to $22 at H.C. Wainwright

Feb 12, 2025 07:37AM Anaptysbio (ANAB) to Resume Trading at 8 a.m.

Feb 12, 2025 07:30AM Anaptysbio (ANAB) Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Feb 12, 2025 07:17AM Anaptysbio (ANAB) Halted, News Pending Ahead of Top-line Data from Phase 2b Trial of Rosnilimab

Feb 4, 2025 06:40AM H.C. Wainwright Reiterates Neutral Rating on AnaptysBio (ANAB)

Feb 3, 2025 07:30AM Vanda Pharmaceuticals (VNDA) and Anaptys (ANAB) Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab

Jan 6, 2025 10:35AM TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'

Jan 3, 2025 08:23AM Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies

Dec 20, 2024 10:26AM Increasing unusual option volume: QUBT CE GALT TSEM ICLN ANAB MVST BBD KULR FREY RGTI OLN NTR

Dec 18, 2024 10:06AM AnaptysBio (ANAB) PT Lowered to $20 at Truist Securities

Dec 12, 2024 07:18AM AnaptysBio (ANAB) PT Lowered to $36 at Guggenheim

Dec 12, 2024 05:59AM Increasing unusual option volume: ANAB RGTI CADL QUBT GLBE SFIX OLLI AON

View Older Stories